BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Now in its tenth year, BioPharm America creates a robust exchange among hundreds of executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size and stage, from mature to startup. The event brings dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.

A primary focus of BioPharm America™ is the one-to-one meetings driven by partneringONE®, the industry’s most robust software platform. Delegates can request and schedule meetings tailored to their strategic business goals to create a dynamic personalized agenda that includes regular alerts for further meeting opportunities.
The impetus behind this intensive business development activity is a two-day conference program that features thought leaders and executives from across the life science industry. To help bring attention to early stage projects and small entrepreneurial companies, BioPharm America features special tracks specifically designed for startups and young companies to get on the radar of the global life science community and to make the connections that matter. Engaging panel discussions cover topics of interest to dealmakers including licensing, investment and business development. 

Leading pharmaceutical companies attend BioPharm America in search of innovation, such as Amgen, AstraZeneca, Bayer HealthCare, Biogen Idec, Boehringer Ingelheim, Genentech, Sanofi/Genzyme, Gilead, Ironwood, Johnson & Johnson Innovation, Merck, Novo Nordisk, Nycomed, Pfizer, and Shire. Held in Boston each September, the event attracted 850+ delegates from 525 companies who participated in 2,350+ scheduled one-to-one meetings in 2016.